Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

Issue : The Pharmaceutical Journal, 25 July/1 August 2015, Vol 295, No 7872/3

Sort by: Newest first Oldest first A-Z Z-A

  • Progesterone could be of benefit in women with breast cancer, after research discovers how it modulates the actions of the oestrogen receptor. In the image, a mammogram showing a tumour in the breast

    Progesterone receptor could slow breast cancer growth Subscription

    17 JUL 2015 14:53 By Bea Perks

    Researchers have discovered why breast cancer patients whose tumours display both oestrogen and progesterone receptors have the best chance of survival.

  • Tuesday 8 September: RPS Faculty webinar Subscription

    17 JUL 2015 14:48

    Royal Pharmaceutical Society (RPS) Faculty webinar, ‘You, your professional practice and the Faculty’. Learn about how using the Faculty assessment supports your professional practice. Find out how the Faculty supports the forthcoming continuing fitness to practise requirements; provides evidence ...

  • Robert Lees dies Subscription

    17 JUL 2015 14:47

    On 10 July 2015, Robert Lees FRPharmS, aged 88, of Sudbury, Suffolk. Mr Lees registered with the Society in 1949.

  • New indication for Simponi Subscription

    17 JUL 2015 11:34

    According to the updated summary of product characteristics (SPC), Simponi (golimumab; Merck Sharp & Dohme) is now indicated for the treatment of adults with severe, active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated C-reactive protein or magnetic resonance imaging evidence or both, who have had an inadequate response to, or are intolerant to, nonsteroidal anti-inflammatory drugs. Further changes to the SPC reflect this ...

  • MenACWY vaccine in Wales Subscription

    17 JUL 2015 11:29

    A combined vaccine that protects against the A,C,W and Y strains of meningococcal disease (MenACWY) is being introduced in Wales, replacing the existing meningitis C jab. From August 2015, the vaccine will be offered to all students aged under 25 years who are attending university for the first time this autumn. There will also be a catch-up programme for all 14–18 year olds over the next two years. 

  • Increase in harm from synthetic cannabinoid use Subscription

    17 JUL 2015 11:27

    Public Health England has published a notice alerting healthcare professionals to the recent increase in harm caused by synthetic cannabinoid use. The notice provides some examples of available synthetic cannabinoids and describes the symptoms that may arise from acute toxicity. It is available from Central Alerting System ...

  • The psychoactive ingredient in cannabis has medical benefits including providing pain relief to patients but it also has some unwanted side effects such as changes in mood, memory or perception. In the image, a cannabis plant

    Medical benefits of cannabis can be separated from unwanted side effects Subscription

    17 JUL 2015 11:25

    Scientists have found that inhibiting the effects of a certain receptor in the brains of mice can prevent negative effects of cannabis but keeps benefits such as pain relief.

  • ‘Debranding’ of branded products Subscription

    17 JUL 2015 11:05 By Mark Burdon

    For some years now, certain manufacturers have been removing the brand name of a medicine and relaunching the product as a generic — so called “debranding”. The aim of this exercise is to circumvent the Pharmaceutical Price Regulation Scheme (PPRS) and allow the manufacturer to increase the price to the NHS.

  • Supplementation with omega 3 and antioxidants can have significant effects in patients with minor cognitive impairment

    Fish oil and antioxidants help clear Alzheimer’s proteins in brains of people without the disease Subscription

    16 JUL 2015 16:40

    A study finds that supplements can help clear amyloid-β protein, which accumulates in the brain during Alzheimer’s disease, but only in patients with minor cognitive impairment or no disease.

  • The US Food and Drug Administration (FDA) has approved brexpiprazole (Otsuka Pharmaceutical’s Rexulti) for the treatment of adults with schizophrenia. In the image, Building 66 of the FDA

    FDA approves brexpiprazole for schizophrenia and depression Subscription

    16 JUL 2015 9:34

    The US Food and Drug Administration has approved brexpiprazole for the treatment of adults with schizophrenia and as add-on therapy in patients with major depressive disorder.

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.

Pharmaceutical Journal Jobs

More jobs